PD-L1 Cancer Research Results

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.


Lung, Lung Cancer: Click to Expand ⟱
Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4)

Scientific Papers found: Click to Expand⟱
1030- BBR,    Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
- in-vitro, Lung, H460
PD-L1↓, TumCG↓, Ki-67↓, cl‑Casp3↑,
1022- EDM,    Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis
- in-vivo, Lung, H1975 - in-vitro, Lung, H1650
TumCG↓, Apoptosis↑, TumCCA↑, PD-L1↓, MUC1-C↓, TumVol↓,
1036- EGCG,    Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
- in-vitro, Lung, A549 - in-vitro, Lung, LU99
PD-L1↓, EGF↓, Akt↓,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
1021- HNK,    Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
- in-vivo, Lung, NA
PD-L1↓, T-Cell↑, CD4+↑, CD8+↑, TumCG↓,
1025- LT,  Api,    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- in-vivo, Lung, NA
TumCG↓, Apoptosis↑, PD-L1↓, p‑STAT3↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
1044- Myr,    Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
- in-vitro, Lung, NA
PD-L1↓, IDO1↓,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics

EGF↓, 1,  

Core Metabolism/Glycolysis

IDO1↓, 1,  

Cell Death

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 2,   cl‑Casp3↑, 1,   YAP/TEAD↓, 1,  

DNA Damage & Repair

P53↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

miR-34a↑, 1,   p‑PI3K↓, 1,   p‑STAT3↓, 1,   TAZ↓, 1,   TumCG↓, 5,  

Migration

Ki-67↓, 1,   MUC1-C↓, 1,  

Angiogenesis & Vasculature

p‑EGFR↓, 1,  

Immune & Inflammatory Signaling

CD4+↑, 1,   PD-L1↓, 8,   T-Cell↑, 1,  

Clinical Biomarkers

p‑EGFR↓, 1,   Ki-67↓, 1,   PD-L1↓, 8,  

Functional Outcomes

TumVol↓, 1,  

Infection & Microbiome

CD8+↑, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


Functional Outcomes

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
1 Berberine
1 Evodiamine
1 EGCG (Epigallocatechin Gallate)
1 Gallic acid
1 Honokiol
1 Luteolin
1 Apigenin (mainly Parsley)
1 Melatonin
1 Myricetin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:15  Cells:%  prod#:%  Target#:243  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page